IXICO plc has completed a placing, subscription and retail offer
IXICO plc has raised US$5 million (£4.05 million) through an over-subscribed placing, subscription and retail offer, issuing 42,621,508 new ordinary shares at 9.5 pence per share, a premium to the price at the time. This important fundraising initiative enables the company to further its pioneering work in neuroscience through advanced imaging and data analytics.
IXICO is a leading medical imaging services provider, specializing in supporting clinical trials for pharmaceutical and biotech companies. With a global network of imaging sites and its custom TrialTracker platform, IXICO offers advanced imaging analytics and digital biomarker services for a variety of neurological diseases, including Alzheimer’s, Huntington’s, Parkinson’s and rare neurological disorders. The company is committed to regulatory compliance and has extensive experience in early-phase clinical development and extended longitudinal studies.
Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised IXICO plc on this transaction.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreOmer Engineering has completed an IPO
Omer Engineering Ltd. has successfully launched its IPO on the Tel Aviv Stock Exchange, pricing shares as part of a plan to raise approximately US$94 million at an implied pre-money valuation of around US$313 million. The offering included both newly issued shares and a secondary sale by existing shareholders, who retained a significant majority stake post-IPO. This transaction underscores strong investor interest in scaling the company’s operations and enhancing its capital.
Learn moreSmart Capital has finalized a rights issue
Smart Capital S.p.A. has finalized a rights issue to continue executing its growth plan and increase its investment capacity. The fundraising supports the expansion of its investment portfolio and the strengthening of its positions in higher-quality investee companies with stronger growth prospects.
Learn more